-
1
-
-
84893772728
-
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
-
Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509
-
(2014)
Ann Rheum Dis
, vol.73
, pp. 492-509
-
-
Smolen, J.S.1
Landewe, R.2
Breedveld, F.C.3
-
2
-
-
79955826864
-
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
-
Braun J, van den Berg R, Baraliakos X et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 896-904
-
-
Braun, J.1
van den Berg, R.2
Baraliakos, X.3
-
3
-
-
84960126976
-
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update
-
Gossec L, Smolen JS, Ramiro S et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016;75:499-510
-
(2016)
Ann Rheum Dis
, vol.75
, pp. 499-510
-
-
Gossec, L.1
Smolen, J.S.2
Ramiro, S.3
-
4
-
-
0033524159
-
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial
-
Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-9
-
(1999)
Lancet
, vol.354
, pp. 1932-1939
-
-
Maini, R.1
St Clair, E.W.2
Breedveld, F.3
-
5
-
-
0033611472
-
A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
-
Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9
-
(1999)
N Engl J Med
, vol.340
, pp. 253-259
-
-
Weinblatt, M.E.1
Kremer, J.M.2
Bankhurst, A.D.3
-
6
-
-
84889688016
-
Inequities in access to biologic and synthetic DMARDs across 46 European countries
-
Putrik P, Ramiro S, Kvien TK et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 2014;73:198-206
-
(2014)
Ann Rheum Dis
, vol.73
, pp. 198-206
-
-
Putrik, P.1
Ramiro, S.2
Kvien, T.K.3
-
7
-
-
84960851952
-
The changing landscape of biosimilars in rheumatology
-
Dö rner T, Strand V, Cornes P et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis 2016;75:974-82
-
(2016)
Ann Rheum Dis
, vol.75
, pp. 974-982
-
-
Dörner, T.1
Strand, V.2
Cornes, P.3
-
8
-
-
84878622273
-
Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target?
-
Modena V, Bianchi G, Roccatello D. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target? Autoimmun Rev 2013;12:835-8
-
(2013)
Autoimmun Rev
, vol.12
, pp. 835-838
-
-
Modena, V.1
Bianchi, G.2
Roccatello, D.3
-
9
-
-
79959479569
-
Use of biologics in rheumatoid arthritis: current and emerging paradigms of care
-
Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther 2011;33:679-707
-
(2011)
Clin Ther
, vol.33
, pp. 679-707
-
-
Curtis, J.R.1
Singh, J.A.2
-
10
-
-
33644952525
-
-
CHMP/437/04Rev1 (2 October 2016, date last accessed)
-
European Medicines Agency. Guideline on similar biological medicinal products. CHMP/437/04Rev1. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/ Scientific_guideline/2014/10/WC500176768.pdf (2 October 2016, date last accessed)
-
(2014)
Guideline on similar biological medicinal products
-
-
-
11
-
-
85052631837
-
-
(2 October 2016, date last accessed)
-
US Food and Drug Administration. Biologics price competition and innovation. http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/ ucm216146.pdf. (2 October 2016, date last accessed)
-
Biologics price competition and innovation
-
-
-
14
-
-
85016808670
-
-
(27 February 2017, date last accessed). April
-
Remicade Prescribing Information. Janssen Biotech, Inc. April 2016. http://www.janssen.com/australia/sites/www_ janssen_com_australia/files/product/pdf/remicade_pi.pdf. (27 February 2017, date last accessed)
-
(2016)
Janssen Biotech, Inc
-
-
-
15
-
-
84951020928
-
A randomized, phase I pharmacokinetic study comparing SB2 and infliximab reference product (Remicade®) in healthy subjects
-
Shin D, Kim Y, Kim YS, Kö rnicke T, Fuhr R. A randomized, phase I pharmacokinetic study comparing SB2 and infliximab reference product (Remicade®) in healthy subjects. Biodrugs 2015;29:381-8
-
(2015)
Biodrugs
, vol.29
, pp. 381-388
-
-
Shin, D.1
Kim, Y.2
Kim, Y.S.3
Körnicke, T.4
Fuhr, R.5
-
16
-
-
84941584714
-
A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy
-
Choe J-Y, Prodanovic N, Niebrzydowski J et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2015;76:58-64
-
(2015)
Ann Rheum Dis
, vol.76
, pp. 58-64
-
-
Choe, J.-Y.1
Prodanovic, N.2
Niebrzydowski, J.3
-
17
-
-
0034735842
-
Infliximab and methotrexate in the treatment of rheumatoid arthritis
-
Lipsky PE, van der Heijde D, St. Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602
-
(2000)
N Engl J Med
, vol.343
, pp. 1594-1602
-
-
Lipsky, P.E.1
van der Heijde, D.2
St Clair, E.W.3
-
18
-
-
67449124635
-
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockage
-
Smolen JS, Han C, van der Heijde DM et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockage. Ann Rheum Dis 2009;68:823-7
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 823-827
-
-
Smolen, J.S.1
Han, C.2
van der Heijde, D.M.3
-
19
-
-
85052664041
-
-
(27 February 2017, date last accessed)
-
European Medicines Agency. Remicade: EPAR-product information (SmPC). 2016. http://www.ema.europa.eu/docs/ en_GB/document_library/EPAR_-_Product_Information/ human/000240/WC500050888.pdf (27 February 2017, date last accessed)
-
(2016)
Remicade: EPAR-product information (SmPC)
-
-
-
21
-
-
84859853303
-
Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice
-
Anderson J, Caplan L, Yazdany J et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res 2012;64:640-7
-
(2012)
Arthritis Care Res
, vol.64
, pp. 640-647
-
-
Anderson, J.1
Caplan, L.2
Yazdany, J.3
-
22
-
-
79951506884
-
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials
-
Felson DT, Smolen JS, Wells G et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 404-413
-
-
Felson, D.T.1
Smolen, J.S.2
Wells, G.3
-
23
-
-
0032981611
-
How to read radiographs according to the Sharp/van der Heijde method
-
van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999;26:743-5
-
(1999)
J Rheumatol
, vol.26
, pp. 743-745
-
-
van der Heijde, D.1
-
24
-
-
84903597970
-
Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations
-
Shankar G, Arkin S, Cocea L et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J 2014;16:658-73
-
(2014)
AAPS J
, vol.16
, pp. 658-673
-
-
Shankar, G.1
Arkin, S.2
Cocea, L.3
-
25
-
-
84965033914
-
Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systemic review and meta-analysis of drug registries and health care databases
-
Souto A, Maneiro JR, Gó mez-Reino JJ. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systemic review and meta-analysis of drug registries and health care databases. Rheumatology 2016;55:523-34
-
(2016)
Rheumatology
, vol.55
, pp. 523-534
-
-
Souto, A.1
Maneiro, J.R.2
Gómez-Reino, J.J.3
-
26
-
-
10744223002
-
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial
-
Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 2004;363:675-81
-
(2004)
Lancet
, vol.363
, pp. 675-681
-
-
Klareskog, L.1
van der Heijde, D.2
de Jager, J.P.3
-
27
-
-
84938518501
-
Relationship between disease activity indices and their individual components and radiographic progression in RA: a systemic literature review
-
Navarro-Compá n V, Gherghe AM, Smolen JS et al. Relationship between disease activity indices and their individual components and radiographic progression in RA: a systemic literature review. Rheumatology 2015;54:994-1007
-
(2015)
Rheumatology
, vol.54
, pp. 994-1007
-
-
Navarro-Compán, V.1
Gherghe, A.M.2
Smolen, J.S.3
-
28
-
-
17244364098
-
Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the antitumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study
-
Smolen JS, Han C, Bala M et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the antitumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005;52:1020-30
-
(2005)
Arthritis Rheum
, vol.52
, pp. 1020-1030
-
-
Smolen, J.S.1
Han, C.2
Bala, M.3
-
29
-
-
84874422827
-
Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis
-
Binder NB, Puchner A, Niederreiter B et al. Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis. Arthritis Rheum 2013;65:608-17
-
(2013)
Arthritis Rheum
, vol.65
, pp. 608-617
-
-
Binder, N.B.1
Puchner, A.2
Niederreiter, B.3
-
30
-
-
34548183243
-
Double-blinded infliximab dose escalation in patients with rheumatoid arthritis
-
Rahman MU, Strusberg I, Geusens P et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:1233-8
-
(2007)
Ann Rheum Dis
, vol.66
, pp. 1233-1238
-
-
Rahman, M.U.1
Strusberg, I.2
Geusens, P.3
-
31
-
-
84962037330
-
A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study
-
Yoo DH, Racewicz A, Brzezicki J et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther 2016;18:82
-
(2016)
Arthritis Res Ther
, vol.18
, pp. 82
-
-
Yoo, D.H.1
Racewicz, A.2
Brzezicki, J.3
-
32
-
-
84883746643
-
Biosimilars to treat inflammatory arthritis: the challenge of proving identity
-
Kay J, Smolen JS. Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis 2013;72:1589-93
-
(2013)
Ann Rheum Dis
, vol.72
, pp. 1589-1593
-
-
Kay, J.1
Smolen, J.S.2
-
33
-
-
84984596871
-
Clinical trials of biosimilars should become more similar
-
Kay J, Isaacs JD. Clinical trials of biosimilars should become more similar. Ann Rheum Dis 2017;76:4-6
-
(2017)
Ann Rheum Dis
, vol.76
, pp. 4-6
-
-
Kay, J.1
Isaacs, J.D.2
-
34
-
-
84980418189
-
United States Health Care Reform
-
Obama B. United States Health Care Reform. JAMA 2016;316:525-32
-
(2016)
JAMA
, vol.316
, pp. 525-532
-
-
Obama, B.1
-
35
-
-
84964570093
-
Editorial: biosimilars: new or dé jàvu?
-
Kay J. Editorial: biosimilars: new or dé jàvu? Arthritis Rheum 2016;68:1049-52
-
(2016)
Arthritis Rheum
, vol.68
, pp. 1049-1052
-
-
Kay, J.1
|